Funder: Foundation for Women's Cancer
Due Dates (Anticipated): December 2026 (Full proposal) | October 2027 (LOI)
Funding Amounts: $50,000 for one year
Summary: Supports precision-based clinical and translational research to improve outcomes for high-risk and poor-prognosis endometrial cancer.
Key Information: Research must take place at a U.S. institution; non-SGO members need an SGO co-investigator or sponsor.
Description
The Foundation for Women’s Cancer (FWC) offers this grant within its Endometrial/Uterine Cancer Grants category. It supports research to improve outcomes for patients with high-risk and poor-prognosis endometrial cancer, including serous tumors and sarcomas.
Priority goes to studies integrating precision-based tools and molecular diagnostics into clinical and translational research. Approaches may include circulating tumor DNA (ctDNA), genomic and gene-expression profiling, proteomics, and other emerging technologies. The goal is to improve risk stratification, guide treatment selection, monitor therapeutic response, and identify mechanisms of resistance. The grant honors Wilma Williams and the work and dedication of gynecologic oncologists.
